TABLE 1.
Demographics and baseline characteristics of AMA‐positive patients
| Characteristics | PBC (n = 568) | Non‐PBC liver diseases (n = 51) | Non‐liver diseases (n = 88) |
| Age | 56 (49–64) | 53 (47–60) | 56 (44–72) |
| Female gender, n (%) | 481 (84.7) | 38 (74.5) | 73 (83.0) |
| AMA‐M2, U/ml | 70 (23–143) | 12 (12–20) b | 16 (4–52) b |
| ANA positivity a , n (%) | 421 (92.9) | 22 (57.9) b | 71 (92.2) |
| ALP, ULN | 1.39 (0.98–2.21) | 0.78 (0.64–1.29) b | 0.59 (0.48–0.76) b |
| GGT, ULN | 3.49 (1.76–7.24) | 1.82 (0.91–2.98) b | 0.76 (0.47–1.16) b |
| ALT, ULN | 1.25 (0.73–1.95) | 4.38 (1.28–7.23) b | 0.48 (0.30–0.76) b |
| AST, ULN | 1.57 (0.97–2.31) | 3.23 (1.63–7.17) b | 0.66 (0.49–0.83) b |
| ALB, g/L | 39.5 (34.8–42.4) | 37.6 (32.0–42.3) b | 36.8 (32.2–41.3) b |
| GLO, g/L | 35.1 (31.7–40.1) | 30.5 (27.9–38.5) b | 30.8 (27.4–36.3) b |
| TBIL, umol/L | 16.1 (11.3–26.5) | 24.5 (14.7–72.4) b | 9.8 (7.4–15.1) b |
| IgG, mg/dl | 1650 (1370–2020) | 1715 (1298–2330) | 1500 (1270–1838) b |
| IgM, mg/dl | 329 (217–510) | 142 (110–229) b | 130 (88–209) b |
Abbreviations: ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANA, antinuclear antibodies; AST, aspartate aminotransferase; GGT, gamma‐glutamyl transpeptidase; GLO, globulin; IgG, immunoglobulin G; IgM, immunoglobulin M; TBIL, total bilirubin; ULN, upper limit of normal.
a
Available in 568 patients.
b
Refers significantly different from the variables of patients with PBC.